comparemela.com
2
3
4
5
6
7
8
Latest Breaking News On - Robert bissonnette - Page 1 : comparemela.com
Ruxolitinib Consistent in Safety, Tolerability Over 52-Weeks in Children with Extensive Atopic Dermatitis
Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.
Chicago
Illinois
United-states
Robert-bissonnette
Innovaderm-research
Innovaderm-research-robert-bissonnette
Revolutionizing-atopic-dermatitis
Maximum-use-trial
Global-assessment
Treatment-success
Dermatology-life-quality-index
Patient-oriented-eczema-measure
JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis
Researchers found that the percentage of patients with a PASI 75 response was higher among those receiving JNJ-77242113 vs placebo.
Montreal
Quebec
Canada
Robert-bissonnette
Janssen-research
Innovaderm-research
Healthday-news
New-england-journal
Psoriasis-area
Severity-index
Robert Bissonnette, MD: Safety Profile, Future Research on New Oral IL-23 Inhibitor for Psoriasis
During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics.
Robert-bissonnette
Innovaderm-research
Chief-executive-officer
Il-23
Coral
Inhibitor
Jnj-2113
Jnj
Bissonnette
Interview
Safety
Phase
Robert Bissonnette, MD: Discussing the First Oral IL-23 Inhibitor for Psoriasis
In this interview, Bissonnette spoke on the significance of the recent topline data on JNJ-2113 for patients with plaque psoriasis.
Robert-bissonnette
Innovaderm-research
Chief-executive-officer
Psoriasis
Pso
Plaque
Jnj-2113
Coral
Il-23
Inhibitor
Bissonnette
Nejm
JNJ-77242113 Shows Greater Efficacy Than Placebo for Plaque Psoriasis
Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide.
Montreal
Quebec
Canada
Robert-bissonnette
Janssen-research
Innovaderm-research
Healthday-news
New-england-journal
Psoriasis-area
Severity-index
vimarsana © 2020. All Rights Reserved.